Patients injected with contrast material were about twice as likely as those who didnt get the chemical to develop hyperthyroidism, when the gland produces too much thyroid hormone and can cause rapid or irregular heart rates, according to a study today in the Archives of Internal Medicine.
Researchers from The University of Texas at Austins Department of Chemical Engineering are the first to show that mechanical property changes in cells may be responsible for cancer progression a discovery that could pave the way for new approaches to predict, treat and prevent cancer.
A new study of local kidney cancer patients shows a strong link to diabetes, with the most advanced cancers found in those with the worst control over their blood sugar
Higher than normal levels of lead in the blood may signal a risk two times higher than average of developing renal cell carcinoma in smokers, according to medical researchers.
Want to go on a date with Denise Richards and help cancer all at the same time? Heres your chance.
According to a new study a set of less-explored cells in the tumor microenvironment may probably serve as essential gatekeepers against cancer progression and metastasis.
Roswell Park Cancer Institute held a press conference this morning to announce the development of an investigational cancer vaccine.
We begin the year with a presentation titled Novel RCC Mutations, by Astrid van der Veldt, M.D., recorded at the 10th International Kidney Cancer Symposium, held in October, 2011, in Chicago. Then, Jessica Zublin explains what it's like to be young adult diagnosed with kidney cancer, and why it is very important for patients be highly proactive in their interactions with medical professionals.
Electronic health records (EHRs) are transforming the way medicine is practiced. With EHRs, providers can access their patients' health information instantaneously. And EHRs are about more than just data, they are about people. They contain the narrative of a patient's health history. That's why ensuring the security of EHRs is a top priority for providers.
Novelos Therapeutics Enrolls First Patient in Phase 1b Trial in Solid Tumors With (131)I-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic. Expects to Begin Phase 2 Proof-of-Concept Trials in First Quarter of 2013.